Clinical Trial Update: Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MEGF0444A in combination with carboplatin, paclitaxel, and bevacizumab in patients with advanced or recurrent non-squamous non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• MEGF0444A
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED